SVB Leerink

Trivest Announces Promotions Across the Firm

Retrieved on: 
Tuesday, February 1, 2022
Professional Services, Small Business, Other Professional Services, Finance, Consulting, Banking, University, Growth, Strategy, Mergers & Acquisitions, Program, Technology, Mergers and acquisitions, Wharton School of the University of Pennsylvania, Real estate, Express Oil Change & Tire Engineers, HBM, Moses Austin, Northwestern University, Marketing, Lehman Brothers, Houlihan Lokey, Total, IntraLinks, Investment, Micah, Inc. (magazine), Phi Beta Kappa, Associate, Vanderbilt University, Siemens, Notre Dame, Company, Business development, SVB Leerink, Solution, Champaign County, Illinois, Engineering, Piper Sandler Companies, Kellogg School, Theology, PPR, Board, Partner, Regions Financial Corporation, Stanford University, Plan, Lincoln International, Renewable energy, Financial services, Bank, Economics, Economic geography, Trivest

Trivest Partners (Trivest or the Firm) is pleased to announce the following promotions a recognition of accomplishment that fully exemplifies the depth of talent and experience on the internally-grown Trivest team.

Key Points: 
  • Trivest Partners (Trivest or the Firm) is pleased to announce the following promotions a recognition of accomplishment that fully exemplifies the depth of talent and experience on the internally-grown Trivest team.
  • Todd joined Trivest in 2008 and manages all operational aspects of the Firm including overall strategy, investor relations, human resources, finance/accounting, and marketing.
  • Ryan joined Trivest in 2019 and presides over all aspects of strategy, design, production, and management of the Trivest brand.
  • Were thrilled to recognize their accomplishments and contributions to the firm, said Troy Templeton, Managing Partner at Trivest.

Olink to present at February investor conferences

Retrieved on: 
Tuesday, February 1, 2022
CFO, CEO, SVB Leerink, Patient, Proteomics, GLOBE, Science, Pharmaceutical industry

UPPSALA, Sweden, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Olink) (Nasdaq: OLK), today announced that Jon Heimer, CEO, and Oskar Hjelm, CFO, will participate in the following virtual investor conferences:

Key Points: 
  • UPPSALA, Sweden, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Olink) (Nasdaq: OLK), today announced that Jon Heimer, CEO, and Oskar Hjelm, CFO, will participate in the following virtual investor conferences:
    BTIG hosted events are intended for prospective and existing BTIG clients only.
  • To listen to the live event, please contact your BTIG representative with interest.
  • A live and archived webcast of the SVB Leerink conference will be available on the Events section of the Companys website at https://investors.olink.com/news-events/events .
  • Olink Holding AB (Nasdaq: OLK) is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients.

Immutep to Present at February Investor Conferences

Retrieved on: 
Monday, January 31, 2022
LAG-3, Patient, APC, NASDAQ, Australian Securities Exchange, Infection, Immunotherapy, Technology, ASX, Degenerative disease, Cancer, Autoimmune disease, Q&A, GLOBE, IMM, SVB Leerink, BIO, Conference, Immutep, Antibody, Security (finance), Vaccine

SYDNEY, AUSTRALIA, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep or the Company), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, announced today that Immutep CEO Marc Voigt has been invited to participate in the following investor conferences scheduled to take place in February 2022.

Key Points: 
  • SYDNEY, AUSTRALIA, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep or the Company), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, announced today that Immutep CEO Marc Voigt has been invited to participate in the following investor conferences scheduled to take place in February 2022.
  • 2022 BIO CEO & Investor Conference: Hybrid Event
    1-on-1 Meetings: Management will be available for 1-on-1 meetings with institutional investors.
  • Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders.
  • Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.

OptimizeRx to Participate in Upcoming February Investor Conferences

Retrieved on: 
Monday, January 31, 2022
CEO, Private Securities Litigation Reform Act, Forward-looking statement, Patient, Organization, Digital health, Intention, Company, Regulation, GLOBE, SVB Leerink, Conference, Medtech, U.S. Securities and Exchange Commission, Management

A fireside chat with Will Febbo, CEO, OptimizeRx:

Key Points: 
  • A fireside chat with Will Febbo, CEO, OptimizeRx:
    OptimizeRxs leadership team will be available for virtual one-on-one meetings.
  • OptimizeRx is the best-in-class health technology company enabling care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey.
  • These forward-looking statements are based on the Companys current expectations and assumptions regarding the Companys business, the economy, and other future conditions.
  • Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements.

Akouos to Participate in Upcoming February Virtual Investor Conferences

Retrieved on: 
Monday, January 31, 2022
EST, Webcast, Neurotology, NASDAQ, Sensorineural hearing loss, Genetic, Hearing loss, GLOBE, AKUS, AAV, SVB Leerink, Conference, Genetics, Software, Pharmaceutical industry, Akouo

BOSTON, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (Akouos) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that members of the management team will participate in two upcoming virtual investor conferences in February:

Key Points: 
  • BOSTON, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (Akouos) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that members of the management team will participate in two upcoming virtual investor conferences in February:
    Cowen 2nd Annual Genetic Medicines Summit.
  • To access the webcast, please go to the Akouos website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required.
  • Akouos is a precision genetic medicine company dedicated to developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for individuals living with disabling hearing loss worldwide.
  • Headquartered in Boston, Akouos was founded in 2016 by leaders in the fields of neurotology, genetics, inner ear drug delivery, and AAV gene therapy.

PatientsLikeMe Announces Dr. Atul Dhir as CEO; Adds Industry Veterans to Board of Directors

Retrieved on: 
Wednesday, January 19, 2022
Software, Internet, Managed Care, General Health, Health, Data Management, Technology, Mobile, Wireless, WR Hambrecht + Co, Silicon, Patient, Technology, Hambrecht & Quist, Health, Consumer Technology Association, Board of directors, Alta Partners, Organization, Infant, Knowledge, SVB Leerink, Growth, CEO, Leadership, UnitedHealth Group, Manning, SVB, Industry, Aetna, Founder, PatientsLikeMe, Hambrecht, Chase Bank, Vice, Director, Board, Management, Pharmaceutical industry, Hospital, Optum

As a physician and a scientist, Dr. Dhir brings more than 20 years experience leading and building innovative companies across a broad range of healthcare delivery and technology.

Key Points: 
  • As a physician and a scientist, Dr. Dhir brings more than 20 years experience leading and building innovative companies across a broad range of healthcare delivery and technology.
  • The companys new Board of Directors is comprised of industry veterans with strong track records of founding and growing disruptive healthcare-related businesses:
    Larry Renfro, Chairman of the Board; Founder and Managing Partner of Optum Ventures.
  • Dr. Hudson has more than 20 years experience founding, growing, and investing in healthcare technology, services, and digital health.
  • He has successfully founded several companies that developed and distributed prescription and over-the-counter products to major chains in the US.

BTIG Healthcare Investment Banking Adds Mikhail Keyserman, CMT, CFTe, as Managing Director to Bolster Biotechnology Client Resources

Retrieved on: 
Tuesday, January 11, 2022
Professional Services, Other Professional Services, Finance, Consulting, Banking, Accounting, City, ETF, Research, Technology, Health, ATM, CFTE, Partner, Adoption, Initial public offering, CIOS, Industry, CMT, SVB Leerink, LLC, Head, Roman Catholic Diocese of La Crosse, Telecommunication, Financial services, Public relations, Citigroup

BTIG announced today that Mikhail Keyserman, CMT, CFTe, has transitioned into the firms Healthcare Investment Banking division.

Key Points: 
  • BTIG announced today that Mikhail Keyserman, CMT, CFTe, has transitioned into the firms Healthcare Investment Banking division.
  • In his new role as a Managing Director and biotechnology specialist, he will focus on identifying investment banking and capital markets opportunities across the biotech industry.
  • Stone, Managing Director, Head of BTIG Healthcare Investment Banking.
  • Healthcare Investment Banking continues to be a key area of focus at BTIG.

Intra-Cellular Therapies Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Retrieved on: 
Friday, January 7, 2022
808, State Street, Cantor, Prospectus, Therapy, Company, Equity capital markets, Needham & Company, Telephone, Psychiatry, Cell, Vesey Street, SVB Leerink, Central nervous system, U.S. Securities and Exchange Commission, BofA Securities, Security (finance), Attention, SEC, Broadridge Financial Solutions, Lists of diseases, File, LLC, Sale, GLOBE, CNS, J.P. Morgan & Co., Nasdaq, Nobel Prize, RBC Capital Markets

In addition, the underwriters have exercised in full their option to purchase an additional 1,428,571 shares.

Key Points: 
  • In addition, the underwriters have exercised in full their option to purchase an additional 1,428,571 shares.
  • All of the shares in the offering were sold by Intra-Cellular Therapies, with gross proceeds to Intra-Cellular Therapies of approximately $460.0 million and net proceeds of approximately $433.7 million, after deducting underwriting discounts and commissions and estimated offering expenses.
  • J.P. Morgan, SVB Leerink, BofA Securities, Evercore ISI and RBC Capital Markets acted as joint book-running managers for the offering.
  • The company leverages this intracellular approach to develop innovative treatments for people living with complex psychiatric and neurologic diseases.

Amylyx Pharmaceuticals Announces Pricing of Upsized Initial Public Offering of Common Stock

Retrieved on: 
Friday, January 7, 2022
Pharmaceutical, Health, Clinical Trials, 808, State Street, Prospectus, Form, Equity capital markets, Amyotrophic lateral sclerosis, Telephone, SVB Leerink, U.S. Securities and Exchange Commission, Exercise, Medication, Security (finance), Neurodegeneration, Attention, SEC, Sale, ALS, Hong Kong national security law, Nasdaq, Pharmaceutical industry

Amylyx Pharmaceuticals, Inc. (Amylyx), a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, today announced the pricing of its upsized initial public offering of 10,000,000 shares of common stock pursuant to registration statements on Form S-1 filed with the U.S. Securities and Exchange Commission (SEC) at an initial public offering price of $19.00 per share.

Key Points: 
  • Amylyx Pharmaceuticals, Inc. (Amylyx), a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, today announced the pricing of its upsized initial public offering of 10,000,000 shares of common stock pursuant to registration statements on Form S-1 filed with the U.S. Securities and Exchange Commission (SEC) at an initial public offering price of $19.00 per share.
  • All of the shares of common stock are being offered by Amylyx.
  • Amylyx has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions.
  • Amylyx' common stock is expected to begin trading on the Nasdaq Global Select Market under the ticker symbol "AMLX" on January 7, 2022.

Intra-Cellular Therapies Prices Public Offering of Common Stock

Retrieved on: 
Wednesday, January 5, 2022
808, State Street, Therapy, Prospectus, Company, Equity capital markets, Forward-looking statement, Needham & Company, Telephone, Psychiatry, Cell, Vesey Street, SVB Leerink, Central nervous system, U.S. Securities and Exchange Commission, BofA Securities, Annual report, Security (finance), Attention, Private Securities Litigation Reform Act, SEC, Broadridge Financial Solutions, Lists of diseases, File, LLC, Sale, GLOBE, CNS, J.P. Morgan & Co., Nasdaq, Nobel Prize, RBC Capital Markets

NEW YORK, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc.(Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the pricing of its previously announced underwritten public offering of 9,523,810 shares of its common stock at a public offering price of $42.00 per share.

Key Points: 
  • NEW YORK, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc.(Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the pricing of its previously announced underwritten public offering of 9,523,810 shares of its common stock at a public offering price of $42.00 per share.
  • All of the shares in the offering will be sold by Intra-Cellular Therapies, with gross proceeds to Intra-Cellular Therapies expected to be $400.0 million before deducting underwriting discounts and commissions and offering expenses.
  • J.P. Morgan, SVB Leerink, BofA Securities, Evercore ISI and RBC Capital Markets are acting as joint book-running managers for the offering.
  • Forward-looking statements include statements, other than statements of historical fact, regarding, among other things, the completion and timing of the public offering and the anticipated total gross proceeds from the offering.